非小细胞肺癌驱动基因的分子变化:从诊断到向治疗
Anna Grodzka1, Agnieszka Knopik-Skrocka1, Katarzyna Kowalska2
1Department of Cell Biology, Faculty of Biology, Adam Mickiewicz University of Poznan, Poland.
EXCLI journal
|June 22, 2023
概括
分子诊断对于非小细胞肺癌 (NSCLC) 治疗至关重要. 识别基因变异可以实现向治疗,并改善患者在肺癌护理中的治疗结果.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 非小细胞肺癌 (NSCLC) 是全球癌症死亡的主要原因.
- 组织学和免疫组织化学分析不足以指导NSCLC治疗.
- 驱动基因中的分子变化在NSCLC中普遍存在,特别是腺癌.
研究的目的:
- 突出分子诊断在NSCLC中的重要性.
- 强调基因分析在个性化肺癌治疗中的作用.
- 审查针对性治疗和正在进行的NSCLC临床试验的进展.
主要方法:
- 关于NSCLC分子诊断的当前文献的综述.
- 对驱动基因 (例如EGFR,KRAS,ALK) 的遗传变异的分析.
- 讨论用于分子分析的下一代测序 (NGS).
主要成果:
- 分子诊断在NSCLC患者中识别了可操作的目标.
- 基因变异频率因种族和吸烟状况而异.
- 最近批准的向疗法 (氨酸激酶抑制剂,免疫检查点抑制剂) 已经改变了NSCLC的治疗方法.
结论:
- 对个性化NSCLC治疗来说,分子分析是必不可少的.
- 针对性疗法和新的治疗策略为肺癌患者提供了更好的治疗结果.
- 目前正在进行的研究,包括对miRNA和CAR-T细胞的临床试验,有望在NSCLC管理方面取得进一步进展.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:39lncRNA - Long Non-coding RNAs
8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K